Forge Biologics, a Columbus, OH-based provider of a gene therapy-focused contract development and manufacturing organization, raised $90M in Series C funding.
The round. which brought total funding raised to date to $330m, was led by Drive Capital and Aisling Capital.
The company intends to use the funds to expand client offerings, including proprietary technologies, manufacturing systems, cell lines, and additional services to bolster its end-to-end manufacturing platform.
Led by CEO Timothy J. Miller, Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Through its 200,000 square foot cGMP facility dedicated to AAV viral vector manufacturing, Forge will expand the number of offerings available to clients to help scale gene therapy programs from research to clinical and commercial manufacturing in its 20 cGMP suites utilizing its operational 50L, 500L, 1,000L and 5,000L bioreactors.
FinSMEs
12/09/2022